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Introduction
Primary peritoneal serous papillary carcinoma (PPSPC) is an 
uncommon malignancy emerging in the abdominal or pelvic peri-
toneal lining and causing severe ascites. It was first described by 
Swerdlow [1] in 1959 and presents predominantly in elderly and 
post-menopausal women. It is a rare disease with an incidence of 
4.62 per million inhabitants in the USA, as presented in a large ex-
amination by Goodman and Shvetsov [2]. The pathological fact 
that it was nearly indistinguishable from papillary serous carci-
noma of the ovary made it difficult to differentiate and diagnose. 
Therefore, a set of specific diagnostic criteria was established by the 
Gynecologic Oncology Group in 1993, although by that time less 
than 250 cases of PPSPC were reported [3]. The consensus meeting 
agreed on the criteria illustrated in table 1.
The establishment of these criteria led to a notable increase in 
the diagnosis of PPSPC in the past years and to a better under-
standing of its presentation and treatment. Nevertheless, much re-
mains indefinite about this malignancy.
In recent years, a remarkable increase of the diagnostic fre-
quency has been noted due to the better understanding of the clini-
cal presentation und behavior of PPSPC [4]. Because of the biologi-
cal and pathological similarities that PPSPC shares with ovarian 
serous tumors, it is likely that both malignancies have a common 
molecular pathogenesis arising from mesothelial cells under Mul-
lerian influence [2]. However, the pathogenesis and etiology of this 
disease still remains largely unknown.
The recommended therapy includes a doublet intravenous 
chemotherapy with taxol and platin, which has shown greater re-
sponse rates in several studies than previous chemotherapy proto-
cols with alkylating agents. A retrospective multicenter study per-
formed by Unal et al. [5] including patients with PPSPC showed a 
superior median overall survival for patients treated with the com-
bination cisplatin/paclitaxel compared to carboplatin/paclitaxel 
(70.3 vs. 41 months) as first-line treatment. During the last decades 
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Summary
Background: Primary peritoneal serous papillary carci-
noma is a rare malignant epithelial tumor which was 
first described in 1959. Peritoneal serous papillary carci-
noma arises from the peritoneal epithelium and origi-
nates from a single or multicentric focus of the perito-
neum involving the peritoneum of the abdomen and pel-
vis. The involvement of retroperitoneal lymph nodes oc-
curs in 64% of the patients diagnosed with this 
malignancy. So far, there is no report about inguinal 
lymph node metastasis in this disease. Case Report: We 
present a rare case of a 63-year-old female patient who 
developed singular inguinal lymph node metastasis 1 year 
after cytoreductive surgery and hyperthermic intraperi-
toneal chemotherapy due to peritoneal serous papillary 
carcinoma. The lymph node metastasis was found by 
computed tomography (CT) scan and was resected and 
histologically confirmed. The postoperative course was 
uneventful, and the patient was discharged on postop-
erative day 1. The last CT scan 24 months after initial 
 cytoreduction and 12 months after lymph node resection 
showed no further tumor recurrence. Conclusion: This 
case report should raise the awareness of potentially un-
expected presentation of extraperitoneal metastasis and 
highlights the importance of patient follow-up including 
clinical examination and CT scans of thorax/abdomen/
pelvis following a systematic schedule.
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and after the development of cytoreductive surgery (CRS), more 
patients were treated with a combination of CRS and hyperthermic 
intraperitoneal chemotherapy (HIPEC) in addition to intravenous 
chemotherapy, thus showing remarkable results. Nam et al. [6] 
showed a significantly longer median survival in patients who had 
optimal cytoreduction (largest residual tumor mass <1.0 cm) than 
those who had suboptimal cytoreduction (41 vs. 10 months, 
respectively).
Despite the peritoneal spreading of the tumor, it is known that 
pelvic and para-aortic lymph nodes can also be affected by PPSPC 
with a frequency of up to 72% [7]. In case of lymph node involve-
ment, Dubernard et al. [8] showed that lymphadenectomy seemed to 
be beneficial in a small series of 19 patients and reported an overall 
survival of 83% after 3 years. In few cases breast and/or axillar lymph 
node metastases have been reported; however, it is of great impor-
tance to differentiate these from primary tumors of the breast [9, 10].
Case Report
We report on a 63-year-old female patient with PPSPC who had no further 
medical history, previous surgeries, or comorbidities. The patient presented to 
the emergency room of a nearby local hospital with abdominal distension last-
ing for 3 weeks as well as pain in the lower abdomen, especially postprandial 
and while standing. After diagnostic laparoscopy and histopathologic diagnosis 
of PPSPC the tumor was declared inoperable and palliative chemotherapy was 
recommended. The patient was referred to our department for a second opin-
ion. We repeated diagnostic laparoscopy to verify the option for CRS and 
HIPEC and staged a Peritoneal Cancer Index (PCI) of 12 with little involve-
ment of the small bowel mesentery (fig. 1). The recommendation of the inter-
disciplinary tumor board was in favor of CRS and HIPEC. Primary resection 
included infragastric omentectomy, appendectomy, pelvic peritonectomy, peri-
tonectomy of the abdominal wall, and mesentery of the small bowel in January 
2015. The duration of the procedure was 243 min, and complete cytoreduction 
could be achieved (CC 0/1). There were no signs of iliac lymph node metastases 
or ovarian metastases. HIPEC was conducted through a closed circulation sys-
tem with 75 mg/m2 cisplatin and 15 mg/m2 doxorubicin over 60 min. The can-
cer antigen 125 (CA-125) dropped from 22 to 8.4 kU/l after CRS and HIPEC as 
a sign of cytoreduction. The diagnosis of PPSPC was histologically confirmed 
and showed an MIB-1 of 25%. The postoperative course was uneventful. The 
patient was discharged 8 days after surgery and was enrolled as an out-patient 
in our clinic for follow-up. After surgical treatment the case was discussed in 
our interdisciplinary tumor board. The recommendation was to surveil the pa-
tient with clinical examinations every 3 months and computed tomography 
(CT) scan every 6 months, with no further chemotherapy.
CT scan 6 months after CRS and HIPEC excluded tumor recurrence, whilst 
CT scan after 12 months presented a suspicious inguinal lymph node without 
peritoneal tumor recurrence (fig.  2). Clinically, the patient reported neither 
signs of abdominal discomfort nor palpable solid mass nor ascites. The CA-125 
slightly increased to 9.1 kU/l. The case was discussed for another time at the 
interdisciplinary tumor conference, which recommended the resection of the 
inguinal lymph node sized 25 × 15 × 10 mm. This resection was carried out in 
February 2016. The histological findings confirmed the origin of PPSPC. The 
postoperative CA-125 was 7.5 kU/l in May 2016. The clinical course of the pa-
tient was uneventful, presenting without further tumor recurrence 2 years after 
CRS and HIPEC in January 2017. The interdisciplinary tumor conference rec-
ommended again in favor of a watch-and-wait strategy without indication for 
systemic chemotherapy. The patient is currently still alive and well; her last fol-
low-up was in January 2017, i.e. 2 years after CRS and HIPEC. Her weight is 
constant, physical examination was unremarkable, and CT scan showed no 
changes to the previous follow-up and no tumor recurrence.
Discussion
PPSPC is a rare malignant epithelial tumor found predomi-
nantly in elderly and post-menopausal women.
The most characteristic presentation of PPSPC is diffuse in-
volvement of the peritoneum with massive ascites, mesenteric and 
omental nodules, or even omental cake. It rarely metastasizes to 
the liver, lung, or brain [11]. The median survival time from the 
diagnosis of PPSPC has been reported to be around 11–17 months 
[12]. To our knowledge, we are describing the first case of inguinal 
lymph node metastasis of PPSPC.
So far, due to its rarity, PPSPC has been mostly discussed und 
studied in the literature by means of single case reports. It has shown 
a variety of clinical presentation and spreading patterns. Ranging 
from a single colonic mass [13] to distant lymph nodes without in-
traperitoneal dissemination [14], the understanding of the clinico-
pathological behavior of PPSPC has been much of a challenge.
The involvement of lymph nodes and the spreading pattern of 
the malignant cells of PPSPC through the lymphatic vessel and 
lymph nodes have been poorly defined. Steinhagen and Sehouli 
[15] noted in their review of existing literature that around two-
thirds of patients suffering from PPSPC appear to have lymphatic 
metastasis of the retroperitoneum. In a further three cases a meta-
static spreading to the breast and/or axillar lymph nodes has been 
described. In these cases, it was important to distinguish PPSPC 
from primary breast cancer and its metastases [10]. Our case did 
not show any retroperitoneal lymph node metastases, neither at the 
initial CRS and HIPEC procedure nor in the follow-up CT scans.
The lymph drainage pattern of the peritoneum is complex and 
differentiates between parietal and visceral peritoneum. Whereas 
the parietal part drains to parietal lymph nodes lying behind the 
peritoneum and leading to axillary, superficial inguinal and lumbar 
lymph nodes, lymph of the visceral peritoneum joins preaortic 
groups of nodes surrounding the abdominal aorta and drains via 
the cisterna chyli to the thoracic duct [16].
Inguinal lymph nodes are a common site of metastasis for ma-
lignancies located in the pelvis, lower extremities, and back. The 
deep inguinal lymph nodes receive afferents from superficial ingui-
nal nodes, whereas those receive lymph from the lower extremities, 
external genitalia, anus, and infraumbilical region of the anterior 
abdominal wall. Tumors that frequently metastasize to inguinal 
lymph nodes are malignant lymphoma, squamous cell carcinoma 
Table 1. Criteria for primary peritoneal serous papillary carcinoma
1 Both of the ovaries are either absent, normal in size, or enlarged by a  
benign process
2 The bulk of the tumor is on the peritoneum, and extraovarian  
involvement should be greater than on the ovarian surface
3 In case of an ovarian involvement, this should be either confined to  
the surface epithelium, with absence of cortical invasion or involving  
the ovarian surface and the underlying cortical stroma, but less than  
5 × 5 mm in diameter
4 Histological and cytological characteristics of the tumor are predomi-
nantly of the serous type
Inguinal Lymph Node Metastasis 1 Year after CRS 
and HIPEC
Visc Med 2018;34:307–309 309
of the vulva or penis, and malignant melanoma of the legs. The 
most common gastrointestinal tumors to metastasize to inguinal 
nodes are squamous cell carcinoma of the anus and adenocarci-
noma of the lower third of the rectum [17]. None of these tumors 
were present in our patient.
In our case, we reported on a 63-year-old patient with PPSPC 
who underwent CRS and HIPEC and had a good clinical course. 
CRS and HIPEC was carried out in January 2015, with an initial 
PCI of 12. 1 year later, the patient developed an inguinal lymph 
node metastasis without any intra-abdominal tumor recurrence. 
The lymph node was surgically resected in February 2016, and his-
tology confirmed the origin of PPSPC. A watch-and-wait strategy 
was decided without indication for systematic chemotherapy; 2 
years after CRS and HIPEC the patient is alive and well, showing 
no further recurrence of tumor.
We consider this finding as important since it is the first case of 
inguinal lymph node metastasis of PPSPC ever reported. It high-
lights the importance of follow-up examinations of patients with 
PPSPC. Despite the absence of intra-abdominal tumor recurrence, 
our patient developed inguinal lymph node metastasis. We recom-
mend postoperative routine examinations with imaging of the tho-
rax, abdomen, and pelvis (CT scan or magnetic resonance imaging 
(MRI)) every 6 months. Postoperative routine examinations help 
to detect tumor recurrence early and in a resectable stage. This re-
port demonstrates that tumor recurrence can also appear in rather 
unlikely localizations of lymphatic drainage such as the inguinal 
lymph nodes and that follow-up examinations should routinely in-
clude physical examinations of these regions.
Conclusion
In conclusion, PPSPC is a rare malignancy with only little un-
derstanding of its origin and behavior; therefore, its pattern is not 
fully known yet. The aim of this case report is to raise awareness of 
a potentially unexpected presentation of extraperitoneal metastasis 
and highlights the importance of patient follow-up including clini-
cal examination and imaging of thorax/abdomen/pelvis (CT scan 
or MRI) following a systematic schedule.
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Fig. 1. Intraoperative 
picture demonstrating 
primary peritoneal  
serous papillary carci-
noma with ascites.
Fig. 2. Computed  
tomography image at 
1-year follow up; the 
right inguinal lymph 
node is presented  
enlarged.
References
 1 Swerdlow M: Mesothelioma of the pelvic peritoneum 
resembling papillary cystadenocarcinoma of the ovary – 
case report. Am J Obstet Gynecol 1959; 77: 197–200.
 2 Goodman MT, Shvetsov YB: Rapidly increasing inci-
dence of papillary serous carcinoma of the peritoneum 
in the United States: fact or artifact? Int J Cancer 2009; 
124: 2231–2235.
 3 Bloss JD, Brady MF, Liao SY, Rocereto T, Partridge EE, 
Clarke-Pearson DL; Gynecologic Oncology Group 
Study: Extraovarian peritoneal serous papillary carci-
noma: a phase II trial of cisplatin and cyclophospha-
mide with comparison to a cohort with papillary se-
rous ovarian carcinoma – a Gynecologic Oncology 
Group Study. Gynecol Oncol 2003; 89: 148–154.
 4 Halperin R, Zehavi S, Langer R, Hadas E, Bukovsky I, 
Schneider D: Primary peritoneal serous papillary carci-
noma: a new epidemiologic trend? A matched-case 
comparison with ovarian serous papillary cancer. Int J 
Gynecol Cancer 2001; 11: 403–408.
 5 Unal OU, Oztop I, Yazici O, et al: Treatment and 
 prognostic factors in primary peritoneal carcinoma: a 
 multicenter study of the Anatolian Society of Medical 
 Oncology (ASMO). Oncol Res Treat 2014; 37: 332–338.
 6 Nam JH, Kim YM, Jung MH, et al: Primary peritoneal 
carcinoma: experience with cytoreductive surgery and 
combination chemotherapy. Int J Gynecol Cancer 2006; 
16: 23–28.
 7 Eltabbakh GH, Mount SL: Lymphatic spread among 
women with primary peritoneal carcinoma. J Surg 
Oncol 2002; 81: 126–131.
 8 Dubernard G, Morice P, Rey A, et al: Lymph node 
spread in stage III or IV primary peritoneal serous 
papillary carcinoma. Gynecol Oncol 2005; 97: 136–141.
 9 Recine MA, Deavers MT, Middleton LP, Silva EG, 
Malpica A: Serous carcinoma of the ovary and perito-
neum with metastases to the breast and axillary lymph 
nodes – a potential pitfall. Am J Surg Pathol 2004; 28: 
1646–1651.
10 Sun JY, Gebre W, Dong YM, Shaun X, Robbins R, 
Podrumar A: Primary peritoneal carcinoma metasta-
sizing to breast: a single case report and literature re-
view from clinic to biology. Cancer Biol Med 2016; 13: 
389–395.
11 Sakakibara Y, Endo S, Yoshida Y, Tanaka Y, Hashi-
moto T, Ohara T: A case of serous surface papillary 
carcinoma of the peritoneum metastatic to the brain 
(Article in Japanese). No Shinkei Geka 2011; 39: 607–
610.
12 Roh SY, Hong SH, Ko YH, et al: Clinical characteristics 
of primary peritoneal carcinoma. Cancer Res Treat 
2007; 39: 65–68.
13 Kim HS, Sung JY, Park WS, Kim YW: Primary perito-
neal serous papillary carcinoma presenting as a single 
colonic mass without peritoneal dissemination. Intern 
Med 2013; 52: 227–232.
14 Yonehara T, Yamaguchi T, Azuma M, Minobe S, 
Sakuragi N: A case of primary serous papillary carci-
noma with unusual clinical presentation: distant lym-
pho nodes metastasis without peritoneal dissemina-
tion. Arch Gynecol Obstet 2008; 278: 579–583.
15 Steinhagen PR, Sehouli J: The involvement of retro-
peritoneal lymph nodes in primary serous-papillary 
peritoneal carcinoma. A systematic review of the liter-
ature. Anticancer Res 2011; 31: 1387–1394.
16 Parungo CP, Soybel DI, Colson YL, et al: Lymphatic 
drainage of the peritoneal space: a pattern dependent 
on bowel lymphatics. Ann Surg Oncol 2007; 14: 286–
298.
17 Hajdarbegovic E, Balak D: Images in clinical medicine. 
Metastatic inguinal lymphadenopathy. N Engl J Med 
2012; 366: 1526.
